Eli Lilly and Company (NYSE:LLY) – Leerink Swann lifted their FY2018 earnings per share estimates for shares of Eli Lilly and in a report issued on Tuesday. Leerink Swann analyst S. Fernandez now anticipates that the company will post earnings per share of $4.67 for the year, up from their previous forecast of $4.66. Leerink Swann has a “Market Perform” rating and a $93.00 price objective on the stock. Leerink Swann also issued estimates for Eli Lilly and’s FY2020 earnings at $5.19 EPS.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping the consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a return on equity of 30.72% and a net margin of 9.90%. Eli Lilly and’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period last year, the business posted $0.88 EPS.
COPYRIGHT VIOLATION WARNING: This story was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.com-unik.info/2017/10/29/fy2018-eps-estimates-for-eli-lilly-and-company-lly-increased-by-leerink-swann.html.
A number of other brokerages have also issued reports on LLY. Morgan Stanley set a $86.00 target price on Eli Lilly and and gave the company a “hold” rating in a research report on Friday, October 6th. BMO Capital Markets set a $73.00 target price on Eli Lilly and and gave the company a “sell” rating in a research report on Tuesday, October 24th. Credit Suisse Group lowered Eli Lilly and from an “outperform” rating to a “neutral” rating and boosted their target price for the company from $84.23 to $88.00 in a research report on Tuesday, October 10th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $95.00 target price (up previously from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $105.00 price objective on shares of Eli Lilly and in a research report on Friday, October 13th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the company’s stock. Eli Lilly and has an average rating of “Hold” and an average price target of $89.76.
Eli Lilly and (NYSE:LLY) opened at 83.86 on Friday. The stock has a market capitalization of $88.47 billion, a P/E ratio of 36.29 and a beta of 0.34. The firm’s 50-day moving average price is $84.90 and its 200 day moving average price is $82.27. Eli Lilly and has a 12-month low of $64.18 and a 12-month high of $89.09.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Ronna Sue Cohen boosted its stake in Eli Lilly and by 0.4% in the second quarter. Ronna Sue Cohen now owns 2,466 shares of the company’s stock valued at $203,000 after acquiring an additional 9 shares in the last quarter. Accredited Investors Inc. boosted its stake in Eli Lilly and by 0.4% in the second quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock valued at $268,000 after acquiring an additional 14 shares in the last quarter. Sunbelt Securities Inc. boosted its stake in Eli Lilly and by 0.5% in the first quarter. Sunbelt Securities Inc. now owns 3,721 shares of the company’s stock valued at $313,000 after acquiring an additional 17 shares in the last quarter. Northwest Quadrant Wealth Management LLC boosted its stake in Eli Lilly and by 0.5% in the first quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock valued at $290,000 after acquiring an additional 19 shares in the last quarter. Finally, Oakworth Capital Inc. boosted its stake in Eli Lilly and by 0.3% in the second quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock valued at $552,000 after acquiring an additional 20 shares in the last quarter. Institutional investors own 75.61% of the company’s stock.
In related news, major shareholder Lilly Endowment Inc sold 205,000 shares of the stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total value of $17,796,050.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold 990,000 shares of company stock worth $82,949,650 in the last three months. 0.20% of the stock is currently owned by corporate insiders.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.48%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is presently 98.58%.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
What are top analysts saying about Eli Lilly and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Company and related companies.